2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
13
Completed
7
Not yet recruiting
2
No longer available
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
437
Carboplatin
322
Nivolumab
292
Cyclophosphamide
281
Specimen Handling
271
Magnetic Resonance Spectroscopy
257
Cisplatin
253
Paclitaxel
248
Radiotherapy
229
Gemcitabine
183
Biopsy
182
Dexamethasone
181
durvalumab
168
atezolizumab
151
Rituximab
138
Doxorubicin
135
Lenalidomide
134
Bevacizumab
133
Docetaxel
131
Ipilimumab
129
Capecitabine
120
Radiation
118
Oxaliplatin
114
Radiosurgery
113
Pemetrexed
112
Etoposide
111
Fluorouracil
110
venetoclax
106
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
zanidatamab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled